Linoy Tsaban

Linoy Tsaban

Auto-generated profile, based on publicly available information

Linoy Tsaban

Gaffin Center for Neuro-Oncology, Sharett Institute for Oncology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel, The Wohl Institute for Translational Medicine, Hadassah Medical Center and Faculty of Me

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JLJakob Landau
Jakob Landau
LTLinoy Tsaban
Linoy Tsaban
AYAdar Yaacov
Adar Yaacov
GCGil Ben Cohen
Gil Ben Cohen
SRShai Rosenberg
Shai Rosenberg
Driver mutations endow tumors with selective advantages and produce an array of pathogenic effects. Determining the function of somatic variants is important for understanding cancer biology and identifying optimal therapies. Here, we compiled a shared dataset from several cancer genomic databases. Two measures were applied to 535 cancer genes based on observed and expected frequencies of driver variants as derived from cancer-specific rates of somatic mutagenesis. The first measure comprised a binary classifier based on a binomial test; the second was tumor variant amplitude (TVA), a continuous measure representing the selective advantage of individual variants. TVA outperformed all other computational tools in terms of its correlation with experimentally derived functional scores of cancer mutations. TVA also highly correlated with drug response, overall survival, and other clinical implications in relevant cancer genes. This study demonstrates how a selective advantage measure based on a large cancer dataset significantly impacts our understanding of the spectral effect of driver variants in cancer. The impact of this information will increase as cancer treatment becomes more precise and personalized to tumor-specific mutations. Significance: A new selective advantage estimation assists in oncogenic driver identification and relative effect measurements, enabling better prognostication, therapy selection, and prioritization.

2 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
OAOrly Avraham
Orly Avraham
TTTomer Tsaban
Tomer Tsaban
ZBZiv Ben-Aharon
Ziv Ben-Aharon
LTLinoy Tsaban
Linoy Tsaban
OSOra Schueler-Furman
Ora Schueler-Furman
Background: Determining a protein’s quaternary state, i.e . how many monomers assemble together to form the functioning unit, is a critical step in protein characterization, and deducing it is not trivial. Many proteins form multimers for their activity, and over 50% are estimated to naturally form homomultimers. Experimental quaternary state determination can be challenging and require extensive work. To complement these efforts, a number of computational tools have been developed for quaternary state prediction, often utilizing experimentally validated structural information. Recently, dramatic advances have been made in the field of deep learning for predicting protein structure and other characteristics. Protein language models that apply computational natural-language models to proteins successfully capture secondary structure, protein cell localization and other characteristics, from a single sequence. Here we hypothesize that information about the protein quaternary state may be contained within protein sequences as well, allowing us to benefit from these novel approaches in the context of quaternary state prediction. Results: We generated embeddings for a large dataset of quaternary state labels, extracted from the curated QSbio dataset. We then trained a model for quaternary state classification and assessed it on a non-overlapping set of distinct folds (ECOD family level). Our model, named QUEEN (QUaternary state prediction using dEEp learNing), performs worse than approaches that include information from solved crystal structures. However, we show that it successfully learned to distinguish multimers from monomers, and that the specific quaternary state is predicted with moderate success, better than a simple model that transfers annotation based on sequence similarity. Our results demonstrate that complex, quaternary state related information is included in these embeddings. Conclusions: QUEEN is the first to investigate the power of embeddings for the prediction of the quaternary state of proteins. As such, it lays out the strength as well as limitations of a sequence-based protein language model approach compared to structure-based approaches. Since it does not require any structural information and is fast, we anticipate that it will be of wide use both for in-depth investigation of specific systems, as well as for studies of large sets of protein sequences. A simple colab implementation is available at: https://colab.research.google.com/github/Orly-A/QUEEN_prediction/blob/main/QUEEN_prediction_notebook.ipynb .


24 November 2025
Verified
Other
Open access
JLJakob Landau
Jakob Landau
LTLinoy Tsaban
Linoy Tsaban
AYAdar Yaacov
Adar Yaacov
GCGil Ben Cohen
Gil Ben Cohen
SRShai Rosenberg
Shai Rosenberg
Driver mutations endow tumors with selective advantages and produce an array of pathogenic effects. Determining the function of somatic variants is important for understanding cancer biology and identifying optimal therapies. Here, we compiled a shared dataset from several cancer genomic databases. Two measures were applied to 535 cancer genes based on observed and expected frequencies of driver variants as derived from cancer-specific rates of somatic mutagenesis. The first measure comprised a binary classifier based on a binomial test; the second was tumor variant amplitude (TVA), a continuous measure representing the selective advantage of individual variants. TVA outperformed all other computational tools in terms of its correlation with experimentally derived functional scores of cancer mutations. TVA also highly correlated with drug response, overall survival, and other clinical implications in relevant cancer genes. This study demonstrates how a selective advantage measure based on a large cancer dataset significantly impacts our understanding of the spectral effect of driver variants in cancer. The impact of this information will increase as cancer treatment becomes more precise and personalized to tumor-specific mutations.Significance:A new selective advantage estimation assists in oncogenic driver identification and relative effect measurements, enabling better prognostication, therapy selection, and prioritization.